Intellia Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, NTLA, Intellia Therapeutics Inc, priceseries

Intellia Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
66.34
Close
62.86
High
67.55
Low
61.26
Previous Close
65.04
Daily Price Gain
-2.18
YTD High
119.65
YTD High Date
Jan 3, 2022
YTD Low
61.26
YTD Low Date
Mar 7, 2022
YTD Price Change
-56.13
YTD Gain
-47.17%
52 Week High
202.73
52 Week High Date
Jun 30, 2021
52 Week Low
46.55
52 Week Low Date
Mar 8, 2021
52 Week Price Change
16.27
52 Week Gain
34.92%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 21. 2017
16.75
Sep 26. 2017
23.48
25 Trading Days
40.18%
Link
LONG
Sep 27. 2017
24.05
Oct 13. 2017
28.65
12 Trading Days
19.15%
Link
LONG
Jan 22. 2018
21.66
Feb 2. 2018
24.30
9 Trading Days
12.19%
Link
LONG
Mar 2. 2018
27.48
Mar 14. 2018
29.90
8 Trading Days
8.82%
Link
LONG
May 7. 2018
21.73
Jun 1. 2018
25.68
18 Trading Days
18.18%
Link
LONG
Feb 25. 2019
14.36
Mar 22. 2019
16.63
19 Trading Days
15.81%
Link
LONG
Jul 17. 2019
16.69
Aug 1. 2019
17.55
11 Trading Days
5.14%
Link
LONG
Oct 30. 2019
11.77
Dec 9. 2019
16.77
27 Trading Days
42.46%
Link
LONG
Oct 5. 2020
20.77
Oct 20. 2020
24.44
11 Trading Days
17.66%
Link
LONG
Nov 3. 2020
25.27
Dec 29. 2020
56.33
38 Trading Days
122.92%
Link
LONG
Jan 5. 2021
61.01
Jan 21. 2021
74.13
11 Trading Days
21.51%
Link
LONG
Mar 9. 2021
57.14
Mar 18. 2021
63.19
7 Trading Days
10.58%
Link
LONG
Mar 26. 2021
64.73
Apr 7. 2021
70.81
7 Trading Days
9.39%
Link
LONG
May 24. 2021
67.00
Jun 16. 2021
76.65
16 Trading Days
14.41%
Link
LONG
Jun 23. 2021
83.59
Jul 13. 2021
144.55
13 Trading Days
72.92%
Link
Company Information
Stock Symbol
NTLA
Exchange
NasdaqGM
Company URL
http://www.intelliatx.com
Company Phone
857-285-6200
CEO
Nessan Bermingham
Headquarters
Massachusetts
Business Address
40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001652130
About

Intellia Therapeutics, Inc. engages in the development of proprietary, potentially curative therapeutics. It provides scientific expertise, clinical development and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Description

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading